Are psychostimulants useful in pervasive developmental disorders?

Evidence is mixed; nonstimulants may be more effective for managing hyperactivity and inattention

Kimberly A. Stigler, MD
Assistant professor

David J. Posey, MD
Assistant professor

Christopher J. McDougle, MD
Albert E. Sterne Professor and chairman

Department of psychiatry
Indiana University School of Medicine
James Whitcomb Riley Hospital for Children
Christian Sarkine Autism Treatment Center
Indianapolis

Psychostimulants benefit many patients with attention-deficit/hyperactivity disorder (ADHD)\(^1\) and thus might seem a logical choice to manage hyperactivity and inattention in youths with a pervasive developmental disorder (PDD). Some PDD patients do respond to psychostimulant therapy, but others worsen—and side effects are common.

Youths with PDDs often exhibit maladaptive behaviors—aggression, self-injury, irritability, hyperactivity, inattention—with repetitive activity patterns and fundamentally impaired social interaction and communication.\(^2\) To help you treat youths with PDD, we draw on the evidence, clinical experience, and our research to suggest psychostimulants’ role in a multimodal approach.

**TARGETING HYPERACTIVITY AND INATTENTION**

**Step 1.** Our approach begins with behavioral therapy (*Figure*), which includes identifying situa-
Psychostimulants in PDDs

Algorithm
Suggested approach to hyperactivity and/or inattention in patients with PDDs

STEP 1
Start with behavioral therapy (BT)

Response

Inadequate response

STEP 2
Continue BT; add alpha-2 adrenergic agonist (AAA); obtain baseline ECG

Response

Inadequate response

STEP 3
Discontinue AAA; start low-dose psychostimulant

Response

Inadequate response

STEP 4
Discontinue psychostimulant; start atypical antipsychotic; obtain baseline liver function, fasting lipid, and glucose values

Response

Inadequate response

To set limits and expectations, the therapist introduces structure such as designating work and break areas and using visual schedules and timers to indicate activity duration. Minimizing distractions and understanding the child’s sensory needs may increase motivation and attention. Initially, the therapist allows numerous breaks and then may slowly decrease them as the child progresses. Tailoring work and play materials to the child’s interests can also help increase attention.

Step 2. Many patients will not respond to behavior therapy alone and will require added drug therapy. Based on evidence, we suggest starting with an alpha-2 adrenergic agonist. Guanfacine may be considered the drug of choice because of clonidine’s higher risk of adverse effects, such as hypotension and sedation. Obtain a baseline ECG with either agent, as clonidine has been associated with rare cardiovascular events.

Clonidine. Two small studies showed that clonidine may be of some benefit to patients with PDDs:

- Results were mixed in a 6-week, double-blind, placebo-controlled, crossover study of clonidine (4 to 10 µg/kg/d) in 8 autistic children ages 5 to 13. Teacher and parent rating instruments reflected significantly improved hyperactivity, irritability, and oppositional behavior. Clinician ratings, however, showed no significant difference between clonidine and placebo. Adverse effects with clonidine included hypotension, sedation, and decreased activity.

- In a 4-week, double-blind, placebo-controlled, crossover study of transdermal clonidine (0.16 to 0.48 mg/kg/d; mean: 3.6 µg/kg/d), clinician ratings showed significantly decreased hyperactivity, impulsivity, and anxiety in 9 autistic males ages 5 to 33. Sedation and fatigue were common adverse effects.
Guanfacine. In a recent retrospective review, we examined outcomes of 80 PDD patients ages 3 to 18 who received guanfacine (0.25 to 9 mg/d; mean: 2.6). Hyperactivity, inattention, and tics decreased in 19 patients (24%) treated for a mean 10 months.

**Step 3.** If clonidine or guanfacine fails to reduce hyperactivity and inattention, discontinue it and consider a psychostimulant trial.

Because psychostimulants’ efficacy in PDDs remains inconclusive, we suggest beginning with a low dosage and carefully monitoring the patient for worsening target symptoms and activation, such as emerging aggression or irritability.

**Step 4.** If hyperactivity and inattention remain prominent and treatment-refractory, we suggest that you discontinue the stimulant and consider an atypical antipsychotic trial. With the atypicals, monitor patients closely for adverse effects, including weight gain, extrapyramidal symptoms, and tardive dyskinesia. Fasting serum glucose and lipid profiles and liver function tests are recommended at least every 6 months and more often in individuals at risk for diabetes or hepatic disease.

Two studies provide evidence of atypicals’ efficacy in PDDs:

- In a 6-week open-label comparison, olanzapine significantly reduced hyperactivity and anger or uncooperativeness in 12 children with autistic disorder, but haloperidol did not. Average weight gain was 9 lbs in patients receiving olanzapine vs 3.2 lbs in those receiving haloperidol.

- An 8-week, double-blind study compared risperidone (0.5 to 3.5 mg/d; mean: 1.8) with placebo in 101 children and adolescents with autistic disorder. Response rates were 69% in the risperidone group and 12% in the control group. Risperidone reduced hyperactivity, aggression, agitation, and repetitive behavior. Adverse drug effects included weight gain (2.7 kg vs. 0.8 kg with placebo), increased appetite, and sedation.

**Psychostimulant Use in PDDs**

Evidence is conflicting on psychostimulant use in patients with PDDs (Table). Early reviews suggested that stimulants were ineffective in PDDs and associated with adverse effects. Some preliminary studies supported that view, but recent reports have been mixed.

**Dextroamphetamine.** Campbell et al published a placebo-controlled study comparing triiodothyronine and dextroamphetamine (mean dosage, 4.8 mg/d; range 1.25 to 10 mg/d) in 16 children ages 3 to 6 (mean, 4.3 years) with diagnoses of autism, schizophrenia, and organic brain syndrome. All diagnostic groups worsened clinically with dextroamphetamine, and adverse effects—hyperactivity, worsened stereotypy, irritability, and decreased appetite—were common.

A subsequent case report found dextroamphetamine effective when 2 patients ages 9 and 12 with PDD were treated with 10 and 5 mg/d, respectively. Hyperactivity, inattention, and impulsivity improved in both patients, and core PDD features did not worsen.

**Levoamphetamine.** In an 8-week, double-blind, crossover comparison with levodopa, levoamphetamine, 3.5 to 42 mg/d (mean, 13.4), worsened symptoms in 12 children ages 3 to 12 who had schizophrenia with autistic features. Stereotypy emerged or increased in 9 of the 11 patients (82%) available for follow-up, and levoamphetamine was poorly tolerated.

**Methylphenidate.** In an early report, methylphenidate decreased hyperactivity and impulsivity in 9 of 15 children (60%) ages 2 to 13 with infantile autism. Dosages of 5 to 10 mg/d or 0.3 to 1 mg/kg/d were given for 2 to 60 weeks (mean, 26). Adverse effects included irritability, insomnia, and anorexia.

A subsequent open-label study and a case report continued
Psychostimulants in PDDs

also indicated that methylphenidate improved hyperactivity in patients with autistic disorder:

- In the 2-week, open-label study,14 9 patients ages 4 to 16 received methylphenidate, 10 to 50 mg/d. Two patients also received haloperidol, 4 and 5 mg/d. Hyperactivity improved significantly, as measured by the Conners Teacher Questionnaire.

- In the case report,15 one child, age 6, was treated with methylphenidate, 10 mg bid, for 31 days. The drug significantly alleviated hyperactivity and improved concentration. Adverse effects included dysphoria and outbursts of anger.

### Table

<table>
<thead>
<tr>
<th>Medication</th>
<th>Type of report</th>
<th>Dosage (mg/d); duration</th>
<th>Outcome</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextroamphetamine</td>
<td>Placebo-controlled10 (N=16)</td>
<td>Mean 4.8; N/A</td>
<td>Clinical worsening</td>
<td>Hyperactivity, irritability, decreased appetite, worsened stereotypy</td>
</tr>
<tr>
<td></td>
<td>Case report11 (N=2)</td>
<td>Mean 7.5; N/A</td>
<td>Improved hyperactivity, inattention, impulsivity</td>
<td>N/A</td>
</tr>
<tr>
<td>Levoamphetamine</td>
<td>Double-blind12 (N=12)</td>
<td>Mean 13.4</td>
<td>Clinical worsening</td>
<td>Stereotypy emerged or worsened</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>Retrospective13 (N=15)</td>
<td>5 to 10; 26 weeks</td>
<td>Improved hyperactivity, impulsivity</td>
<td>Irritability, insomnia, anorexia</td>
</tr>
<tr>
<td></td>
<td>Open-label14 (N=9)</td>
<td>10 to 50; 2 weeks</td>
<td>Improved hyperactivity</td>
<td>Initial mild insomnia</td>
</tr>
<tr>
<td></td>
<td>Case report15 (N=1)</td>
<td>20; 4 weeks</td>
<td>Improved hyperactivity, concentration</td>
<td>Dysphoria, angry outbursts</td>
</tr>
<tr>
<td></td>
<td>Double-blind, placebo-controlled, crossover16 (N=10)</td>
<td>20 mg/d for 2 weeks, 40 mg/d for 2 weeks</td>
<td>Modest benefit over placebo</td>
<td>Statistically similar to placebo</td>
</tr>
<tr>
<td></td>
<td>Double-blind, placebo-controlled, crossover17 (N=13)</td>
<td>0.3 mg/kg and 0.6 mg/kg</td>
<td>Improved hyperactivity, inattention</td>
<td>Social withdrawal, irritability</td>
</tr>
<tr>
<td>Methylphenidate, levoamphetamine, dextroamphetamine, or pemoline</td>
<td>Retrospective18 (N=195)</td>
<td>Various dosages, durations</td>
<td>Patients with, Asperger's disorder were significantly more likely to respond</td>
<td>Agitation, dysphoria, irritability</td>
</tr>
</tbody>
</table>

N/A: not available
Atomoxetine—a nonstimulant, selective norepinephrine reuptake inhibitor—has been approved to treat hyperactivity and inattention in ADHD, but no evidence has been published on its use in PDDs. A study of desipramine—a norepinephrine reuptake inhibitor—may offer some insight into the possible efficacy and tolerability of atomoxetine in PDDs.

Desipramine (mean, 127 mg/d) was compared with the serotonin reuptake inhibitor clomipramine (mean, 153 mg/d) in a 10-week, double-blind, crossover study of 24 autistic patients ages 6 to 23. The agents were equally effective and superior to placebo in decreasing hyperactivity, although desipramine was associated with increased aggression and irritability.

Despite these results with desipramine, research is needed to understand atomoxetine’s potential role in treating hyperactivity and inattention in youths with PDDs.

Controlled trials. These early reports were followed by two double-blind, placebo-controlled, crossover studies of methylphenidate in children with autistic disorder.

- In the first trial, methylphenidate, 10 or 20 mg/d, improved irritability and hyperactivity in 10 children ages 7 to 11 but was only modestly more beneficial than placebo. Side-effect incidence—including decreased appetite, irritability, and insomnia—was similar during active and placebo treatments. Two patients required adjunctive haloperidol for prevailing behavioral problems.

- In the second trial, 8 of 13 children (62%) ages 5 to 11 responded to methylphenidate, 0.3 and 0.6 mg/kg per dose. Hyperactivity and inattention improved significantly, as measured by a minimum 50% decrease in Conners Hyperactivity Index score. Ratings of stereotypy and inappropriate speech also decreased, but no changes were seen in the Child Autism Rating Scale. Adverse effects, which were more common with the 0.6 mg/kg dose, included social withdrawal and irritability.

Retrospective trial. Our group recently completed a retrospective study of 195 youth (mean age, 7.3 years; range, 2 to 19 years) with PDDs treated with a stimulant medication. As a whole, stimulants appeared ineffective.

Analysis of response by PDD subtype found that individuals with Asperger’s disorder—in contrast to those with autistic disorder or PDD not otherwise specified—were significantly more likely to respond to a stimulant medication. Gender, intelligence quotient (IQ), type of stimulant, and dosage did not significantly affect response. Adverse effects—including agitation, dysphoria, and irritability—occurred in 57.5% of the trials.

Atomoxetine. This nonstimulant medication has been approved for treating ADHD. However, research is needed to understand its use in patients with PDDs (Box).19

Summary. These mixed findings—combined with anecdotal reports from physicians describing the onset or exacerbation of hyperactivity, irritability, and aggression—indicate that much more evidence is needed regarding psychostimulant use in patients with PDDs.

To help meet this need, the National Institutes of Mental Health’s Research Units on Pediatric Psychopharmacology (RUPP) autism network recently completed a large, double-blind, placebo-controlled study to investigate methylphenidate’s efficacy and tolerability in PDDs. It is anticipated that the results will help us discern whether factors such as PDD subtype, patient age, dosage, or degree of mental retardation are associated with response.
Related resources


Drug brand names

- Atomoxetine • Strattera
- Clonipramine • Anafranil
- Clonidine • Catapres
- Desipramine • Norpramin
- Dextroamphetammine • Dextrexine, Dextrostat
- Guanfacine • Tenex
- Haloperidol • Haldol
- Levoamphetamine • Adderall
- Levodopa • Dopa, Laradopa
- Methylenphedanate • Ritalin
- Olanzapine • Zypraxa
- Pemoline • Cylert
- Risperidone • Risperdal

Disclosure

Dr. Posey receives research support from Janssen Pharmaceutica and Eli Lilly and Co. and is a speaker for Janssen Pharmaceutica.

Dr. McDougle receives research support from Janssen Pharmaceutica, Pfizer Inc., Eli Lilly and Co., and Bristol-Myers Squibb Co. He is a consultant to or speaker for Janssen Pharmaceutica, Pfizer Inc., Eli Lilly and Co., RepliGen Corp., and Bristol-Myers Squibb Co.

Acknowledgments

This work was supported in part by a Daniel X. Freedman Psychiatric Research Fellowship Award (Dr. Posey), a National Alliance for Research in Schizophrenia and Depression (NARSAD) Young Investigator Award (Dr. Posey), a Research Units on Pediatric Psychopharmacology Grant (U10-MH68766-02) from the National Institute of Mental Health (NIMH) to Indiana University (Dr. McDougle, Dr. Stigler, and Dr. Posey), a Research Career Development Award (K23-MH08627-01) from the NIMH (Dr. Posey), a National Institutes of Health Clinical Research Center grant to Indiana University (M01-RR00750), and a Department of Housing and Urban Development (HUD) grant (B-01-SP-IN-0200) (Dr. McDougle).

References